Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.66 |
| ▸ | BCR | P11274 | 8/20 | 0.66 |
| ▸ | KIT | P10721 | 5/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | PRKCA | P17252 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | ABL2 | P42684 | 1/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100360 | 0.93 | ABL1 (0.67) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3104753 | 0.93 | PDGFRA (0.66) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3100831 | 0.91 | ABL1 (0.68) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3107483 | 0.91 | ABL1 (0.63) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3099014 | 0.90 | PDGFRA (0.71) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3099734 | 0.90 | ABL1 (0.66) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3100631 | 0.89 | ABL1 (0.64) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3104728 | 0.88 | ABL1 (0.76) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3104783 | 0.87 | ABL1 (0.77) | ABL1PDGFRABCRKITPDGFRB | |
| SCHEMBL3099866 | 0.86 | ABL1 (0.74) | ABL1PDGFRABCRKITPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338417-B2 | Compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | claimed |
| US-20100234406-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| EP-2152688-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-02-17 | — | — | EP | claimed |
| WO-2008137794-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2008-11-13 | — | — | WO | claimed |
| US-8338417-B2 | Compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338417-B2 | Compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338417-B2 | Compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20100234406-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100234406-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100234406-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| EP-2152688-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008137794-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137794-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234406-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | ABL1 10/4885PDGFRA 2/4885BCR 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.